REMARKS

The Examiner has delineated the following inventions a being patentably distinct:

Group I: Claims 1-3 and 11-13, drawn to a peptide derived from the amino acid sequence of human WT1 set forth in SEQ. ID NO: 1 and having activity as an HLA-A26-binding cancer antigen peptide, and pharmaceutical compositions comprising the same;

Group II: Claims 4-7, drawn to polynucleotides expressing the peptide, and expression vectors and cells comprising the same, and a method of using the same to synthesize the peptide;

Group III: Claim 8, drawn to an antibody which specifically binds to the peptide;

Group IV: Claim 9, drawn to an antigen-presenting cell comprising a complex of the peptide and HLA-A26 antigen;

Group V: Claim 10, drawn to a CL which recognizes a complex between the peptide and HLA-A26 antigen;

Group VI: Claims 14 and 15, drawn to a complex between the peptide and HLA-A26 antigen;

Group VII: Claims 16-18 drawn to a pharmaceutical composition comprising a peptide of SEQ. ID NO: 3, or an epitope peptide comprising the peptide, or an expression vector containing a polynucleotide encoding the peptide, or a cell comprising the expression vector, or an antigen-presenting cell comprising a complex of the peptide and HLA-A*0201 antigen, or a CTL which recognizes the complex; and

Group VIII: Claims 19 and 20, drawn to a complex of a peptide of SEQ.. ID NO:3 and HLA-A*0201 antigen.

The Examiner further required the election of a single species. Accordingly, Applicants elect without traverse Group I, Claims 1-3 and 11-13 drawn to a peptide derived from the amino acid sequence WT1 set forth in SEQ. ID NO: 1 and having activity as an HLA-A26 binding cancer antigen peptide, and pharmaceutical composition comprising the same. And for a species, Applicants elect peptide of SEQ. ID NO: 9 for examination purpose also without traverse.

Further, Applicants reserve the right to file divisional applications if so desired on the non-elected subject matter and be accorded the benefit of the filing date of the parent application. Divisional applications filed thereafter should not be subject to double-patenting ground of rejection, 35 USC 121, *In re Joyce*, (Comr. Pats 1957) 115 USPQ 412.

Restriction is only proper if the claims of the restricted groups are independent or patentably distinct and there would be a serious burden placed on the Examiner if restriction is not required (M.P.E.P. § 803).

Applicants make no statement regarding the patentable distinctness of the species, but note that for the restriction to be proper there must be patentable differences.

Applicants submit that the above-identified application is now in condition for examination on the merits, and an early notice of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Paul J. Killos
Registration No. 58,014

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 06/04)